> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
- URL: https://www.theamericanquorum.com/fda-approves-first-gene-therapy-sanfilippo-syndrome/
- Published: 2026-09-18T08:26:28.000Z
- Updated: 2026-09-18T08:26:28.000Z
- Description: FDA approval brings the first disease-modifying treatment for children with Sanfilippo syndrome type A, but its $3.95 million price, small trial and intensive follow-up leave access and long-term evidence as key tests.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare

The Food and Drug Administration approved the first treatment for children with Sanfilippo syndrome type A on Thursday, clearing a one-time gene therapy that carried a $3.95 million list price and showed a 23.5-point cognitive-score advantage over untreated patients.

The therapy, Fayuvi, is intended for pediatric patients who still have preserved neurodevelopmental function. The [FDA said](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type?ref=theamericanquorum.com) the approval changes a field in which care had been limited to managing symptoms of a rare inherited disease that progressively damages the brain and nervous system.

## A Treatment Aimed at the Cause

Sanfilippo syndrome type A, also called mucopolysaccharidosis type IIIA, results from changes in the SGSH gene. Those changes leave children without enough sulfamidase, an enzyme needed to break down heparan sulfate inside cells. The material accumulates in the brain and body, contributing to the progressive loss of cognitive, language and motor abilities.

Fayuvi, formally rebisufligene etisparvovec-hopf, uses a modified adeno-associated virus called AAV9 to carry a working copy of SGSH into cells. It is administered as a single intravenous infusion, after which the cells can produce sulfamidase and reduce the harmful buildup. That mechanism targets the underlying enzyme deficiency rather than only the complications it causes.

The approved indication is narrower than a blanket authorization for every child with the disorder. The official [prescribing information](https://www.ultragenyx.com/USPI%5Ffayuvi?ref=theamericanquorum.com) specifies pediatric patients with preserved neurodevelopmental function, making early diagnosis and referral particularly important because neurological losses from the disease are generally irreversible.

## Small Study, Large Measured Difference

The FDA based efficacy on an open-label, single-arm study and long-term follow-up rather than a randomized placebo-controlled trial. Seventeen treated children were compared with 27 untreated children from an external natural-history cohort. From 24 to 60 months of age, treated children gained or maintained developmental skills while the comparison group lost skills.

The difference in the mean change on the Bayley-III cognitive scale was 23.5 points in favor of Fayuvi, with a 95 percent confidence interval of 17.2 to 29.9\. The label reports a median follow-up of 4.2 years, ranging from 2.9 to 7.8 years. It also says 15 of 16 assessed children maintained at least a 50 percent reduction in cerebrospinal-fluid heparan sulfate exposure at 24 months.

Those findings are consequential, but their limits matter. The study was small, lacked random assignment and relied on a historical comparison group. A [regulatory account](https://www.fiercepharma.com/pharma/fda-approves-ultragenyx-gene-therapy-fayuvi-rare-neurodegenerative-disorder?ref=theamericanquorum.com) noted that the approval followed an earlier FDA rejection tied to manufacturing issues, not a finding that the therapy was ineffective.

## Safety Requires Specialized Follow-Up

Fayuvi is not a routine infusion. Patients receive corticosteroids beginning one day before treatment and continuing for at least eight weeks. The label calls for liver testing and blood-clotting assessments before infusion, weekly platelet checks for four weeks and monthly monitoring for six months.

Common adverse reactions included elevated liver enzymes, vomiting, fever, reduced white-blood-cell and platelet counts, decreased appetite, nausea and increased amylase. The FDA also warned about thrombotic microangiopathy, infusion reactions and a potential long-term malignancy risk if inserted genetic material integrates into the genome. No thrombotic microangiopathy cases occurred in the clinical studies, according to the company’s [approval statement](https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-approval-fayuvitm-gene-therapy-first-ever?ref=theamericanquorum.com), but monitoring is recommended because the complication has occurred with other AAV therapies.

## A $3.95 Million Access Test

Ultragenyx said commercial doses should reach qualified U.S. treatment centers within 30 to 60 days. The company plans to use specialized centers trained to administer gene therapy and a patient-support program to help families navigate insurance authorization and treatment logistics.

The $3.95 million list price places Fayuvi among the world’s most expensive medicines. Ultragenyx told [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-ultragenyxs-gene-therapy-rare-disorder-2026-09-17/?ref=theamericanquorum.com) that lifetime care for an affected child can exceed $8 million as the disease advances. That comparison does not guarantee coverage, however. Insurers will still have to assess eligibility, evidence, treatment timing and payment arrangements for a one-time therapy whose benefit is expected to unfold over years.

## What the Approval Changes

For families, the immediate change is the arrival of the first FDA-approved option intended to alter the disease course. The [Cure Sanfilippo Foundation](https://curesanfilippofoundation.org/what-is-sanfilippo/?ref=theamericanquorum.com) describes type A as typically the most severe and rapidly progressing form of the syndrome, often bringing earlier loss of speech and walking abilities than other subtypes.

The approval also offers a broader test for rare-disease gene therapy. The measurable cognitive advantage and durable biomarker reductions support the biological case for treatment, while the small, nonrandomized evidence base makes long-term surveillance essential. That follow-up will help show whether the developmental separation persists as children age. Uptake will depend not only on manufacturing and specialized centers, but also on finding children early enough to meet the label’s requirement for preserved function.

Fayuvi therefore represents both a clinical milestone and an implementation challenge. The FDA has opened a treatment path where none existed, but the practical benefit will turn on diagnosis, safety monitoring, insurer decisions and whether eligible children can reach the limited network before the disease takes more of their developmental capacity.